Predictors of Care-Seeking Behavior for Treatment of Urinary Incontinence in Women.

Importance: Urinary incontinence (UI) is a common and treatable medical condition among women, but only approximately one third of women seek care.

Objective: The objective of this study was to determine factors associated with care-seeking behavior in women with UI.

Study Design: This was a cross-sectional study using patient-reported survey data collected by the National Association for Continence from November 2018 to January 2019.

A Plain Language Summary on the Effect of the Medication Vibegron on Blood Pressure and Heart Rate in People With Overactive Bladder.

What Is This Summary About?: This is a plain language summary of an article originally published in the journal . Vibegron is a medicine that was approved by the US Food and Drug Administration (also called FDA) in 2020 for treatment of overactive bladder, a condition that causes a frequent and urgent need to urinate. This study took place before the medicine was approved to look at whether vibegron affects blood pressure or heart rate.

Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study.

What is this summary about? This is a plain language summary of an article originally published in the . Overactive bladder (also called OAB) has been treated with the same type of medicine for more than 40 years. Vibegron is in a newer class of medicine for treating overactive bladder called beta-3 adrenergic receptor agonists.

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?

What is this summary about? This is a plain language summary of an article published in the journal . In 2020, the US Food and Drug Administration (also called the FDA) approved a medicine called vibegron to treat overactive bladder, also called OAB. The key results used to approve vibegron were from the EMPOWUR study.